A new oral testosterone (TLANDO) treatment regimen without dose titration requirement for male hypogonadism

Male hypogonadism (testosterone level < 300 ng/dl) is a clinical syndrome that results from failure of the testis to produce physiological levels of testosterone. As a result, most marketed testosterone replacement therapy products often require multiple dose adjustment clinic visits to achieve the desired eugonadal testosterone levels. Subjects enrolled were on average age of 56 years, with about 17% of subjects older than 65 years. TLANDO restored testosterone levels to the normal range in most hypogonadal males. This new oral testosterone replacement therapy can provide an option for no‐titration oral testosterone replacement therapy. This therapy has the potential to improve patient compliance in testosterone replacement therapy.